biostudies-literatureShen XNational Natural Science Foundation of China2461716https://www.ebi.ac.uk/biostudies/studies/S-EPMC8970858biostudies-literatureUnknown2022<h4>Background</h4>Osteoporosis is a systemic bone disease characterized by reduction of bone content. Bisphosphonates are first-line treatments for osteoporosis, but they have variable effectiveness. Genetic factors may explain these differences. The NF-<i>κ</i>B signaling pathway plays a key role in the regulation of bone metabolism. We aimed to determine whether genetic variations in the NF-<i>κ</i>B signaling pathway affect the effectiveness of alendronate in postmenopausal Chinese women with low bone mass.<h4>Methods</h4>We recruited 455 postmenopausal Han Chinese women with primary osteoporosis or osteopenia aged 48-90 yrs who had experienced no spontaneous menses for at least 1 yr. All participants had dual X-ray absorptiometry (DEXA) bone mineral density (BMD) measurement at baseliEvidence-based complementary and alternative medicine : eCAMAssociation between NF-<i>κ</i>B Signal Pathway-Related Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density.PMC89708582016ZCL J02081770872Hu YLiu LFeng XWang CFu WHua FTan SWang WYuan HShen XLi MfalseAssociation between NF-<i>κ</i>B Signal Pathway-Related Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density.<h4>Background</h4>Osteoporosis is a systemic bone disease characterized by reduction of bone content. Bisphosphonates are first-line treatments for osteoporosis, but they have variable effectiveness. Genetic factors may explain these differences. The NF-<i>κ</i>B signaling pathway plays a key role in the regulation of bone metabolism. We aimed to determine whether genetic variations in the NF-<i>κ</i>B signaling pathway affect the effectiveness of alendronate in postmenopausal Chinese women with low bone mass.<h4>Methods</h4>We recruited 455 postmenopausal Han Chinese women with primary osteoporosis or osteopenia aged 48-90 yrs who had experienced no spontaneous menses for at least 1 yr. All participants had dual X-ray absorptiometry (DEXA) bone mineral density (BMD) measurement at baseli2022-01-01T00:00:00Z20222025-04-26T13:09:53.704Z2025-04-06T14:08:04.347ZS-EPMC89708583536877210.1155/2022/2461716